HXL Stock Overview
Does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hexima Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.013 |
| 52 Week High | AU$0.022 |
| 52 Week Low | AU$0.008 |
| Beta | 0.92 |
| 11 Month Change | 12.50% |
| 3 Month Change | -15.63% |
| 1 Year Change | n/a |
| 33 Year Change | -96.35% |
| 5 Year Change | n/a |
| Change since IPO | -92.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| HXL | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 0.9% |
| 1Y | n/a | 11.0% | 18.4% |
Return vs Industry: Insufficient data to determine how HXL performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how HXL performed against the Australian Market.
Price Volatility
| HXL volatility | |
|---|---|
| HXL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: HXL's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine HXL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Geoffrey Kempler | hexima.com.au |
Hexima Limited does not have significant operations. It focuses on exploration of transactions with third parties, which could enable the value of the company’s assets. Previously, the company was involved in the research and development of pezadeftide for the treatment of onychomycosis.
Hexima Limited Fundamentals Summary
| HXL fundamental statistics | |
|---|---|
| Market cap | AU$2.17m |
| Earnings (TTM) | -AU$933.87k |
| Revenue (TTM) | AU$61.67k |
35.2x
P/S Ratio-2.3x
P/E RatioIs HXL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HXL income statement (TTM) | |
|---|---|
| Revenue | AU$61.67k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$61.67k |
| Other Expenses | AU$995.55k |
| Earnings | -AU$933.87k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0056 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,514.21% |
| Debt/Equity Ratio | 0% |
How did HXL perform over the long term?
See historical performance and comparison